The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson’s disease
- First Online:
- Cite this article as:
- Schillaci, O., Pierantozzi, M., Filippi, L. et al. Eur J Nucl Med Mol Imaging (2005) 32: 1452. doi:10.1007/s00259-005-1922-9
The aim of this study was to evaluate, by means of 123I-FP-CIT SPECT, the effect of chronic treatment with levodopa on striatal dopamine transporter (DAT) in patients with Parkinson’s disease.
Fifteen patients under stable levodopa/carbidopa monotherapy were imaged twice: at baseline on medication and after at least 20 days of treatment wash-out. DAT levels were assessed from SPECT imaging for the entire striatum, the right and left striatum, the right and left putamen and the right and left caudate, as a ratio of regional brain activities using the formula: (striatal region of interest−occipital)/occipital.
During levodopa wash-out, despite a worsening in patients’ clinical disability (H&Y mean stage 2.53±0.58 versus 1.73±0.45 on therapy, p<0.001), striatal 123I-FP-CIT levels were not significantly different from those at baseline in any of the brain regions examined.
The results of this study suggest that levodopa does not affect 123I-FP-CIT brain imaging and confirm that it is not necessary to withdraw this medication to measure DAT levels with SPECT.